<DOC>
	<DOCNO>NCT00525330</DOCNO>
	<brief_summary>To assess safety efficacy chronic therapy KRP-104 , novel DPP-IV inhibitor , patient Type 2 Diabetes stable metformin therapy . In addition , estimate much HbA1c response attributable nocturnal coverage explore .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Placebo-Controlled Study Assess Safety Efficacy KRP-104 Patients With Type 2 Diabetes Inadequately Controlled Metformin Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Age 18 70 year , inclusive ; 2 . Males females nonchildbearing potential ; 3 . Diagnosis type 2 diabetes mellitus accord ; 4 . On stable dose metformin monotherapy randomization ( oral therapy naive study entry 1 . History type 1 diabetes mellitus history diabetic ketoacidosis persistent hypoglycemia ; 2 . History presence alcoholism drug abuse 3 . Typical consumption â‰¥10 drink alcohol weekly ; 4 . Presence follow condition : Significant renal impairment ( glomerular filtration rate &lt; 60 mL/min [ calculate central laboratory ] ) ; Diabetic retinopathy ; Diabetic gastroparesis ; Active liver disease ( asymptomatic nonalcoholic fatty liver disease ) , cirrhosis , symptomatic gallbladder disease ; 5 . Uncontrolled high blood pressure ; 6 . History evidence cardiovascular pulmonary disease 7 . Must meet laboratory Medical History clinical criterion . Please contact recruitment center referral</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>